-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on RxSight, Raises Price Target to $6.3

Benzinga·08/06/2026 19:39:23
Listen to the news
UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.